 MONTREAL, March 10, 2021 GLOBE NEWSWIRE -- Theratechnologies Inc. Theratechnologies TSX: TH NASDAQ: THTX, a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new positive pre-clinical data on TH1902, its lead peptide-drug conjugate PDC for the treatment of sortilin positive SORT1 solid tumors, will be presented in two e-posters during AACR Annual Meeting 2021. 